W
292.65
-6.57 (-2.20%)
| Previous Close | 299.22 |
| Open | 297.38 |
| Volume | 497,795 |
| Avg. Volume (3M) | 836,890 |
| Market Cap | 17,419,735,040 |
| Price / Earnings (TTM) | 26.36 |
| Price / Earnings (Forward) | 22.62 |
| Price / Sales | 6.31 |
| Price / Book | 8.87 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2025 |
| Profit Margin | 22.02% |
| Operating Margin (TTM) | 22.93% |
| Diluted EPS (TTM) | 11.01 |
| Quarterly Revenue Growth (YOY) | 3.90% |
| Quarterly Earnings Growth (YOY) | 18.80% |
| Total Debt/Equity (MRQ) | 78.58% |
| Current Ratio (MRQ) | 1.81 |
| Operating Cash Flow (TTM) | 758.81 M |
| Levered Free Cash Flow (TTM) | 588.83 M |
| Return on Assets (TTM) | 11.61% |
| Return on Equity (TTM) | 40.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Waters Corporation | Bullish | Bearish |
AIStockmoo Score
2.7
| Analyst Consensus | 3.0 |
| Insider Activity | 3.0 |
| Price Volatility | 4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 2.70 |
|
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 98.23% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fundsmith Investment Services Ltd. | 30 Jun 2025 | 1,220,785 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 390.00 (Rothschild & Co, 33.27%) | Buy |
| Median | 338.50 (15.67%) | |
| Low | 315.00 (Deutsche Bank, 7.64%) | Hold |
| 315.00 (Wells Fargo, 7.64%) | Hold | |
| Average | 347.00 (18.57%) | |
| Total | 3 Buy, 3 Hold | |
| Avg. Price @ Call | 299.27 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 09 Oct 2025 | 325.00 (11.05%) | Hold | 330.45 |
| Rothschild & Co | 08 Oct 2025 | 390.00 (33.26%) | Buy | 327.65 |
| Deutsche Bank | 05 Aug 2025 | 315.00 (7.64%) | Hold | 281.19 |
| Wells Fargo | 05 Aug 2025 | 315.00 (7.64%) | Hold | 281.19 |
| Jefferies | 04 Aug 2025 | 385.00 (31.56%) | Buy | 285.59 |
| Baird | 16 Jul 2025 | 352.00 (20.28%) | Buy | 289.56 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 13 Oct 2025 | Announcement | Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics |
| 01 Oct 2025 | Announcement | Waters Corporation Schedules Third Quarter 2025 Earnings Conference Call |
| 26 Aug 2025 | Announcement | Waters Corporation to Present at the Wells Fargo Healthcare Conference |
| 04 Aug 2025 | Announcement | Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |